{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:14:28Z","timestamp":1792602868108,"version":"4.5.0"},"reference-count":128,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The current treatment strategy is still subpar, especially for severe mental\nproblems, despite tremendous progress in the understanding of the central nervous system.\nImproving healthcare usually entails two main approaches: investigating new treatment\napproaches and improving current ones. New pharmacological options include enhanced\nmonoaminergic pharmaceuticals, old treatments reassessed with a better knowledge\nof the biology of mental disease, and medications that target new therapeutic pathways.\nOne major clinical challenge in the treatment of depression is resistance to antidepressant\ndrugs. It appears promising to switch to monotherapy using new multifunctional\nantidepressants and add new atypical antipsychotics, such as brexpiprazole and\naripiprazole. Current efforts are concentrated on unraveling depression's origins and pinpointing\nfresh targets for pharmacological intervention. This review explores encouraging\nnovel pharmacological avenues for major depressive disorder treatment. These include\ntargeting receptors, such as N-methyl-D-aspartate and metabotropic glutamate receptors,\nand employing glutamatergic modulators and various augmentation strategies,\nall of which hold the potential for reversal of depressant effects. Combining innovative\nconcepts with enhancements of existing discoveries may propel antidepressant research\nforward, offering hope for developing compounds that are effective and rapid in their action,\neven among patients who have found limited success with other therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298673342524250109181220","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T01:25:18Z","timestamp":1748222718000},"page":"1121-1135","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring New Frontiers in Pharmacological Treatment of Depression: A Review on Recent Advances"],"prefix":"10.2174","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4660-3603","authenticated-orcid":true,"given":"Muthukumaran","family":"Thulasingam","sequence":"first","affiliation":[{"name":"Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu district, 603203, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3052-9517","authenticated-orcid":true,"given":"Chitra","family":"Vellapandian","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, SRMCollege of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu district,603203, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/515180a","volume":"515","author":"Smith K.","year":"2014","unstructured":"Smith K.; Torres D.I.; Mental health: A world of depression. Nature  2014,515(7526),180-181","journal-title":"Nature"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"Mathers C.D.","year":"2006","unstructured":"Mathers C.D.; Loncar D.; Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med  2006,3(11),e442","journal-title":"PLoS Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2215-0366(16)30024-4","volume":"3","author":"Chisholm D.","year":"2016","unstructured":"Chisholm D.; Sweeny K.; Sheehan P.; Rasmussen B.; Smit F.; Cuijpers P.; Saxena S.; Scaling-up treatment of depression and anxiety: A global return on investment analysis. Lancet Psychiatry  2016,3(5),415-424","journal-title":"Lancet Psychiatry"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3389\/fpsyt.2017.00311","volume":"8","author":"Hanssen H.","year":"2018","unstructured":"Hanssen H.; Minghetti A.; Faude O.; Trucks\u00e4ss S.A.; Zahner L.; Beck J.; Donath L.; Effects of endurance exercise modalities on arterial stiffness in patients suffering from unipolar depression: A randomized controlled trial. Front Psychiatry  2018,8,311","journal-title":"Front Psychiatry"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jad.2016.03.063","volume":"202","author":"Kvam S.","year":"2016","unstructured":"Kvam S.; Kleppe C.L.; Nordhus I.H.; Hovland A.; Exercise as a treatment for depression: A meta-analysis. J Affect Disord  2016,202,67-86","journal-title":"J Affect Disord"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4088\/JCP.v61n0103","volume":"61","author":"Delgado P.L.","year":"2000","unstructured":"Delgado P.L.; Depression: The case for a monoamine deficiency. J Clin Psychiatry  2000,61(6)(Suppl. 6),7-11","journal-title":"J Clin Psychiatry"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/neurolint13030038","volume":"13","author":"Edinoff A.N.","year":"2021","unstructured":"Edinoff A.N.; Akuly H.A.; Hanna T.A.; Ochoa C.O.; Patti S.J.; Ghaffar Y.A.; Kaye A.D.; Viswanath O.; Urits I.; Boyer A.G.; Cornett E.M.; Kaye A.M.; Selective serotonin reuptake inhibitors and adverse effects: A narrative review. Neurol Int  2021,13(3),387-401","journal-title":"Neurol Int"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"946","DOI":"10.4088\/JCP.v69n0610","volume":"69","author":"Vieira M.R.","year":"2008","unstructured":"Vieira M.R.; Salvadore G.; Luckenbaugh D.A.; Manji H.K.; Zarate C.A.; Rapid onset of antidepressant action: A new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry  2008,69(6),946-958","journal-title":"J Clin Psychiatry"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/genes13040646","volume":"13","author":"Kamran M.","year":"2022","unstructured":"Kamran M.; Bibi F.; Rehman U.A.; Morris D.W.; ur. Rehman A, Morris DW. Major depressive disorder: Existing hypotheses about pathophysiological mechanisms and new genetic findings. Genes (Basel)  2022,13(4),646","journal-title":"Genes (Basel)"},{"key":"ref=10","doi-asserted-by":"crossref","DOI":"10.4324\/9781003156727","author":"Koenigsberg J.Z.","year":"2023","unstructured":"Koenigsberg J.Z.;  Depressive disorders: Integrated and unified psychotherapy approaches  2023","journal-title":"Depressive disorders: Integrated and unified psychotherapy approaches"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3390\/ijms25020963","volume":"25","author":"Cardon I.","year":"2024","unstructured":"Cardon I.; Grobecker S.; K\u00fcc\u00fckoktay S.; Bader S.; Jahner T.; Nothdurfter C.; Koschitzki K.; Berneburg M.; Weber B.H.F.; St\u00f6hr H.; H\u00f6ring M.; Liebisch G.; Braun F.; Hampl R.T.; Riemenschneider M.J.; Rupprecht R.; Milenkovic V.M.; Wetzel C.H.; Mitochondrial and cellular function in fibroblasts, induced neurons, and astrocytes derived from case study patients: Insights into major depression as a mitochondria-associated disease. Int J Mol Sci  2024,25(2),963","journal-title":"Int J Mol Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.euroneuro.2013.04.013","volume":"25","author":"Artigas F.","year":"2015","unstructured":"Artigas F.; Developments in the field of antidepressants, where do we go now? Eur Neuropsychopharmacol  2015,25(5),657-670","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jad.2017.07.001","volume":"233","author":"Gadad B.S.","year":"2018","unstructured":"Gadad B.S.; Jha M.K.; Czysz A.; Furman J.L.; Mayes T.L.; Emslie M.P.; Trivedi M.H.; Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks. J Affect Disord  2018,233,3-14","journal-title":"J Affect Disord"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14737175.2017.1341310","volume":"17","author":"Rakesh G.","year":"2017","unstructured":"Rakesh G.; Pae C.U.; Masand P.S.; Beyond serotonin: Newer antidepressants in the future. Expert Rev Neurother  2017,17(8),777-790","journal-title":"Expert Rev Neurother"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.bcp.2007.09.021","volume":"75","author":"Pilc A.","year":"2008","unstructured":"Pilc A.; Chaki S.; Nowak G.; Witkin J.M.; Mood disorders: Regulation by metabotropic glutamate receptors. Biochem Pharmacol  2008,75(5),997-1006","journal-title":"Biochem Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"108687","DOI":"10.1016\/j.neuropharm.2021.108687","volume":"196","author":"Dogra S.","year":"2021","unstructured":"Dogra S.; Conn P.J.; Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders. Neuropharmacology  2021,196,108687","journal-title":"Neuropharmacology"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2470547019837712","DOI":"10.1177\/2470547019837712","volume":"3","author":"Chaki S.","year":"2019","unstructured":"Chaki S.; Koike H.; Fukumoto K.; Targeting of metabotropic glutamate receptors for the development of novel antidepressants. Chronic Stress  2019,3,2470547019837712","journal-title":"Chronic Stress"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.biopsych.2010.06.016","volume":"68","author":"Y\u00fcksel C.","year":"2010","unstructured":"Y\u00fcksel C.; \u00d6ng\u00fcr D.; Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry  2010,68(9),785-794","journal-title":"Biol Psychiatry"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fpsyt.2018.00767","volume":"9","author":"Li C.T.","year":"2019","unstructured":"Li C.T.; Yang K.C.; Lin W.C.; Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: Evidence from clinical neuroimaging studies. Front Psychiatry  2019,9,767","journal-title":"Front Psychiatry"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"590095","DOI":"10.3389\/fpsyt.2020.590095","volume":"11","author":"Poletti S.","year":"2020","unstructured":"Poletti S.; Mazza M.G.; Vai B.; Lorenzi C.; Colombo C.; Benedetti F.; Proinflammatory cytokines predict brain metabolite concentrations in the anterior cingulate cortex of patients with bipolar disorder. Front Psychiatry  2020,11,590095","journal-title":"Front Psychiatry"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1111\/bph.13222","volume":"172","author":"Lodge D.","year":"2015","unstructured":"Lodge D.; Mercier M.S.; Ketamine and phencyclidine: The good, the bad and the unexpected. Br J Pharmacol  2015,172(17),4254-4276","journal-title":"Br J Pharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"444","DOI":"10.2174\/1570159X12666140619204251","volume":"12","author":"Serafini G.","year":"2014","unstructured":"Serafini G.; Howland R.; Rovedi F.; Girardi P.; Amore M.; The role of ketamine in treatment-resistant depression: A systematic review. Curr Neuropharmacol  2014,12(5),444-461","journal-title":"Curr Neuropharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.addr.2012.11.006","volume":"65","author":"Yamashita F.","year":"2013","unstructured":"Yamashita F.; Hashida M.; Pharmacokinetic considerations for targeted drug delivery. Adv Drug Deliv Rev  2013,65(1),139-147","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bph.15753","volume":"179","author":"Borb\u00e9ly \u00c9.","year":"2022","unstructured":"Borb\u00e9ly \u00c9.; Simon M.; Fuchs E.; Wiborg O.; Cz\u00e9h B.; Helyes Z.; Novel drug developmental strategies for treatment-resistant depression. Br J Pharmacol  2022,179(6),1146-1186","journal-title":"Br J Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1743-7075-5-27","volume":"5","author":"Bibi Z.","year":"2008","unstructured":"Bibi Z.; Role of cytochrome P450 in drug interactions. Nutr Metab  2008,5(1),27","journal-title":"Nutr Metab"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/ALN.0b013e31822f16ae","volume":"115","author":"Wang J.","year":"2011","unstructured":"Wang J.; Goffer Y.; Xu D.; Tukey D.S.; Shamir D.B.; Eberle S.E.; Zou A.H.; Blanck T.J.J.; Ziff E.B.; A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats. Anesthesiology  2011,115(4),812-821","journal-title":"Anesthesiology"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s43440-021-00232-4","volume":"73","author":"Kohtala S.","year":"2021","unstructured":"Kohtala S.; Ketamine\u201450 years in use: From anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacol Rep  2021,73(2),323-345","journal-title":"Pharmacol Rep"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41386-023-01629-w","volume":"49","author":"Krystal J.H.","year":"2024","unstructured":"Krystal J.H.; Kavalali E.T.; Monteggia L.M.; Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology  2024,49(1),41-50","journal-title":"Neuropsychopharmacology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6619515","volume":"2021","author":"An X.","year":"2021","unstructured":"An X.; Yao X.; Li B.; Yang W.; Cui R.; Zhao G.; Jin Y.; Role of BDNF-mTORC1 signaling pathway in female depression. Neural Plast  2021,2021,1-8","journal-title":"Neural Plast"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.pnpbp.2019.02.001","volume":"92","author":"Peyrovian B.","year":"2019","unstructured":"Peyrovian B.; Rosenblat J.D.; Pan Z.; Iacobucci M.; Brietzke E.; McIntyre R.S.; The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry  2019,92,387-404","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/HRP.0000000000000183","volume":"26","author":"Henter I.D.","year":"2018","unstructured":"Henter I.D.; Sousa d.R.T.; Zarate C.A.; Glutamatergic modulators in depression. Harv Rev Psychiatry  2018,26(6),307-319","journal-title":"Harv Rev Psychiatry"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jad.2006.03.004","volume":"93","author":"Levy H.U.","year":"2006","unstructured":"Levy H.U.; Javitt D.C.; Gelfin Y.; Gorelik E.; Bar M.; Blanaru M.; Kremer I.; Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord  2006,93(1-3),239-243","journal-title":"J Affect Disord"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.genhosppsych.2015.01.003","volume":"37","author":"Lee E.E.","year":"2015","unstructured":"Lee E.E.; Selva D.M.P.; Liu A.; Himelhoch S.; Ketamine as a novel treatment for major depressive disorder and bipolar depression: A systematic review and quantitative meta-analysis. Gen Hosp Psychiatry  2015,37(2),178-184","journal-title":"Gen Hosp Psychiatry"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-021-00816-x","volume":"35","author":"Henter I.D.","year":"2021","unstructured":"Henter I.D.; Park L.T.; Zarate C.A.; Novel glutamatergic modulators for the treatment of mood disorders: Current status. CNS Drugs  2021,35(5),527-543","journal-title":"CNS Drugs"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.3390\/ph16111572","volume":"16","author":"Vecera C.M.","year":"2023","unstructured":"Vecera C.M.; Courtes C.A.; Jones G.; Soares J.C.; Vieira M.R.; Pharmacotherapies targeting GABA-glutamate neurotransmission for treatment-resistant depression. Pharmaceuticals (Basel)  2023,16(11),1572","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"873693","DOI":"10.3389\/fpsyt.2022.873693","volume":"13","author":"Asghar J.","year":"2022","unstructured":"Asghar J.; Tabasam M.; Althobaiti M.M.; Ashour A.A.; Aleid M.A.; Khalaf I.O.; Aldhyani T.H.H.; A randomized clinical trial comparing two treatment strategies, evaluating the meaningfulness of HAM-D rating scale in patients with major depressive disorder. Front Psychiatry  2022,13,873693","journal-title":"Front Psychiatry"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e0259861","DOI":"10.1371\/journal.pone.0259861","volume":"16","author":"Fenton C.","year":"2021","unstructured":"Fenton C.; McLoughlin D.M.; Usefulness of hamilton rating scale for depression subset scales and full versions for electroconvulsive therapy. PLoS One  2021,16(11),e0259861","journal-title":"PLoS One"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41398-020-01097-6","volume":"11","author":"MahmoudianDehkordi S.","year":"2021","unstructured":"MahmoudianDehkordi S.; Ahmed A.T.; Bhattacharyya S.; Han X.; Baillie R.A.; Arnold M.; Skime M.K.; Williams J.L.S.; Moseley M.A.; Thompson J.W.; Louie G.; Posse R.P.; Craighead W.E.; McDonald W.; Krishnan R.; Rush A.J.; Frye M.A.; Dunlop B.W.; Weinshilboum R.M.; Daouk K.R.; Daouk K.R.; Rush J.; Tenenbaum J.; Moseley A.; Thompson W.; Louie G.; Blach C.; Mahmoudiandehkhordi S.; Baillie R.; Han X.; Bhattacharyya S.; Frye M.; Weinshilboum R.; Ahmed A.; Neavin D.; Liu D.; Skime M.; Rinaldo P.; Fiehn O.; Brydges C.; Mayberg H.; Choi K.S.; Cha J.; Kastenm\u00fcller G.; Arnold M.; Binder E.; Arloth K.J.; Holgado N.A.; Shi L.; Dunlop B.; Craighead E.; McDonald W.; Posse P.R.; Penninx B.; Milaneschi Y.; Jansen R.; Krishnan R.; Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram\/escitalopram in major depression. Transl Psychiatry  2021,11(1),153","journal-title":"Transl Psychiatry"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.3390\/cells11223530","volume":"11","author":"Bourque M.","year":"2022","unstructured":"Bourque M.; Gr\u00e9goire L.; Patel W.; Dickens D.; Snodgrass R.; Paolo D.T.; AV-101, a pro-drug antagonist at the nmda receptor glycine site, reduces l-dopa induced dyskinesias in mptp monkeys. Cells  2022,11(22),3530","journal-title":"Cells"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/ijnp\/pyaa025","volume":"23","author":"Park L.T.","year":"2020","unstructured":"Park L.T.; Kadriu B.; Gould T.D.; Zanos P.; Greenstein D.; Evans J.W.; Yuan P.; Farmer C.A.; Oppenheimer M.; George J.M.; Adeojo L.W.; Snodgrass H.R.; Smith M.A.; Henter I.D.; Vieira M.R.; Mannes A.J.; Zarate C.A.; A randomized trial of the n-methyl-d-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression. Int J Neuropsychopharmacol  2020,23(7),417-425","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"24705470211020446","DOI":"10.1177\/24705470211020446","volume":"5","author":"Hecking J.","year":"2021","unstructured":"Hecking J.; Davoudian P.A.; Wilkinson S.T.; Emerging therapeutics based on the amino acid neurotransmitter system: An update on the pharmaceutical pipeline for mood disorders. Chronic Stress  2021,5,24705470211020446","journal-title":"Chronic Stress"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"948","DOI":"10.7150\/ijbs.6426","volume":"9","author":"Willard S.S.","year":"2013","unstructured":"Willard S.S.; Koochekpour S.; Glutamate, glutamate receptors, and downstream signaling pathways. Int J Biol Sci  2013,9(9),948-959","journal-title":"Int J Biol Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1749-6632.2009.05144.x","volume":"1187","author":"Schmidt H.D.","year":"2010","unstructured":"Schmidt H.D.; Pierce R.C.; Cocaine-induced neuroadaptations in glutamate transmission. Ann N Y Acad Sci  2010,1187(1),35-75","journal-title":"Ann N Y Acad Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.neubiorev.2010.01.013","volume":"35","author":"Wolf M.E.","year":"2010","unstructured":"Wolf M.E.; Ferrario C.R.; AMPA receptor plasticity in the nucleus accumbens after repeated exposure to cocaine. Neurosci Biobehav Rev  2010,35(2),185-211","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/1570159X14666160321123221","volume":"15","author":"Jaso B.A.","year":"2017","unstructured":"Jaso B.A.; Niciu M.J.; Iadarola N.D.; Lally N.; Richards E.M.; Park M.; Ballard E.D.; Nugent A.C.; Vieira M.R.; Zarate C.A.; Therapeutic modulation of glutamate receptors in major depressive disorder. Curr Neuropharmacol  2017,15(1),57-70","journal-title":"Curr Neuropharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/17512433.2017.1253472","volume":"10","author":"Henter I.D.","year":"2017","unstructured":"Henter I.D.; Sousa d.R.T.; Gold P.W.; Brunoni A.R.; Zarate C.A.; Vieira M.R.; Mood therapeutics: Novel pharmacological approaches for treating depression. Expert Rev Clin Pharmacol  2017,10(2),153-166","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e1001566","DOI":"10.1371\/journal.pmed.1001566","volume":"10","author":"Riveros C.","year":"2013","unstructured":"Riveros C.; Dechartres A.; Perrodeau E.; Haneef R.; Boutron I.; Ravaud P.; Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Med  2013,10(12),e1001566","journal-title":"PLoS Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12916-016-0740-1","volume":"14","author":"Dechartres A.","year":"2016","unstructured":"Dechartres A.; Bond E.G.; Scheer J.; Riveros C.; Atal I.; Ravaud P.; Reporting of statistically significant results at ClinicalTrials.gov for completed superiority randomized controlled trials. BMC Med  2016,14(1),192","journal-title":"BMC Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.pnpbp.2016.01.009","volume":"67","author":"Kent J.M.","year":"2016","unstructured":"Kent J.M.; Daly E.; Kezic I.; Lane R.; Lim P.; Smedt D.H.; Boer D.P.; Nueten V.L.; Drevets W.C.; Ceusters M.; Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI\/SNRI in anxious depression. Prog Neuropsychopharmacol Biol Psychiatry  2016,67,66-73","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e00096","DOI":"10.1002\/prp2.96","volume":"3","author":"Lavreysen H.","year":"2015","unstructured":"Lavreysen H.; Ahnaou A.; Drinkenburg W.; Langlois X.; Mackie C.; Pype S.; L\u00fctjens R.; Poul L.E.; Trabanco A.A.; Nu\u00f1ez J.M.C.; Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor. Pharmacol Res Perspect  2015,3(1),e00096","journal-title":"Pharmacol Res Perspect"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.31887\/DCNS.2014.16.2\/mrose","volume":"16","author":"Rose M.","year":"2014","unstructured":"Rose M.; Devine J.; Assessment of patient-reported symptoms of anxiety. Dialogues Clin Neurosci  2014,16(2),197-211","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","volume":"8","author":"Kocarnik J.M.","year":"2022","unstructured":"Kocarnik J.M.; Compton K.; Dean F.E.; Fu W.; Gaw B.L.; Harvey J.D.; Henrikson H.J.; Lu D.; Pennini A.; Xu R.; Ababneh E.; Kangevari A.M.; Abbastabar H.; Elsalam A.S.M.; Abdoli A.; Abedi A.; Abidi H.; Abolhassani H.; Adedeji I.A.; Adnani Q.E.S.; Advani S.M.; Afzal M.S.; Aghaali M.; Ahinkorah B.O.; Ahmad S.; Ahmad T.; Ahmadi A.; Ahmadi S.; Rashid A.T.; Salih A.Y.; Akalu G.T.; Aklilu A.; Akram T.; Akunna C.J.; Hamad A.H.; Alahdab F.; Aly A.Z.; Ali S.; Alimohamadi Y.; Alipour V.; Aljunid S.M.; Alkhayyat M.; Hashiani A.A.; Almasri N.A.; Maweri A.S.A.A.; Almustanyir S.; Alonso N.; Guzman A.N.; Amu H.; Anbesu E.W.; Ancuceanu R.; Ansari F.; Moghaddam A.A.; Antwi M.H.; Anvari D.; Anyasodor A.E.; Aqeel M.; Arabloo J.; Zozani A.M.; Aremu O.; Ariffin H.; Aripov T.; Arshad M.; Artaman A.; Arulappan J.; Asemi Z.; Jafarabadi A.M.; Ashraf T.; Atorkey P.; Aujayeb A.; Ausloos M.; Awedew A.F.; Quintanilla A.B.P.; Ayenew T.; Azab M.A.; Azadnajafabad S.; Jafari A.A.; Azarian G.; Azzam A.Y.; Badiye A.D.; Bahadory S.; Baig A.A.; Baker J.L.; Balakrishnan S.; Banach M.; B\u00e4rnighausen T.W.; Adesi B.F.; Barra F.; Barrow A.; Behzadifar M.; Belgaumi U.I.; Bezabhe W.M.M.; Bezabih Y.M.; Bhagat D.S.; Bhagavathula A.S.; Bhardwaj N.; Bhardwaj P.; Bhaskar S.; Bhattacharyya K.; Bhojaraja V.S.; Bibi S.; Bijani A.; Biondi A.; Bisignano C.; Bj\u00f8rge T.; Bleyer A.; Blyuss O.; Bolarinwa O.A.; Bolla S.R.; Braithwaite D.; Brar A.; Brenner H.; Teixeira B.M.T.; Butt N.S.; Butt Z.A.; Caetano dos Santos F.L.; Cao Y.; Carreras G.; L\u00f3pez C.F.; Cembranel F.; Cerin E.; Cernigliaro A.; Chakinala R.C.; Chattu S.K.; Chattu V.K.; Chaturvedi P.; Ochir C.O.; Cho D.Y.; Christopher D.J.; Chu D.T.; Chung M.T.; Conde J.; Cort\u00e9s S.; Cortesi P.A.; Costa V.M.; Cunha A.R.; Dadras O.; Dagnew A.B.; Dahlawi S.M.A.; Dai X.; Dandona L.; Dandona R.; Darwesh A.M.; Neves d.J.; De la Hoz F.P.; Demis A.B.; Guti\u00e9rrez D.E.; Dhamnetiya D.; Dhimal M.L.; Dhimal M.; Dianatinasab M.; Diaz D.; Djalalinia S.; Do H.P.; Doaei S.; Dorostkar F.; dos Santos Figueiredo F.W.; Driscoll T.R.; Ebrahimi H.; Eftekharzadeh S.; Tantawi E.M.; Abid E.H.; Elbarazi I.; Elhabashy H.R.; Elhadi M.; Jaafary E.S.I.; Eshrati B.; Eskandarieh S.; Esmaeilzadeh F.; Etemadi A.; Ezzikouri S.; Faisaluddin M.; Faraon E.J.A.; Fares J.; Farzadfar F.; Feroze A.H.; Ferrero S.; Desideri F.L.; Filip I.; Fischer F.; Fisher J.L.; Foroutan M.; Fukumoto T.; Gaal P.A.; Gad M.M.; Gadanya M.A.; Gallus S.; Fonseca G.M.; Obsa G.A.; Ghafourifard M.; Ghashghaee A.; Ghith N.; Gholamalizadeh M.; Gilani S.A.; Ginindza T.G.; Gizaw A.T.T.; Glasbey J.C.; Golechha M.; Goleij P.; Gomez R.S.; Gopalani S.V.; Gorini G.; Goudarzi H.; Grosso G.; Gubari M.I.M.; Guerra M.R.; Guha A.; Gunasekera D.S.; Gupta B.; Gupta V.B.; Gupta V.K.; Guti\u00e9rrez R.A.; Nejad H.N.; Haider M.R.; Mirzaian H.A.; Halwani R.; Hamadeh R.R.; Hameed S.; Hamidi S.; Hanif A.; Haque S.; Harlianto N.I.; Haro J.M.; Hasaballah A.I.; Hassanipour S.; Hay R.J.; Hay S.I.; Hayat K.; Heidari G.; Heidari M.; Serna H.B.Y.; Herteliu C.; Hezam K.; Holla R.; Hossain M.M.; Hossain M.B.H.; Hosseini M.S.; Hosseini M.; Hosseinzadeh M.; Hostiuc M.; Hostiuc S.; Househ M.; Hsairi M.; Huang J.; Hugo F.N.; Hussain R.; Hussein N.R.; Hwang B.F.; Iavicoli I.; Ibitoye S.E.; Ida F.; Ikuta K.S.; Ilesanmi O.S.; Ilic I.M.; Ilic M.D.; Irham L.M.; Islam J.Y.; Islam R.M.; Islam S.M.S.; Ismail N.E.; Isola G.; Iwagami M.; Jacob L.; Jain V.; Jakovljevic M.B.; Javaheri T.; Jayaram S.; Jazayeri S.B.; Jha R.P.; Jonas J.B.; Joo T.; Joseph N.; Joukar F.; J\u00fcrisson M.; Kabir A.; Kahrizi D.; Kalankesh L.R.; Kalhor R.; Kaliyadan F.; Kalkonde Y.; Kamath A.; Kameran Al-Salihi N.; Kandel H.; Kapoor N.; Karch A.; Kasa A.S.; Katikireddi S.V.; Kauppila J.H.; Kavetskyy T.; Kebede S.A.; Keshavarz P.; Keykhaei M.; Khader Y.S.; Khalilov R.; Khan G.; Khan M.; Khan M.N.; Khan M.A.B.; Khang Y.H.; Khater A.M.; Khayamzadeh M.; Kim G.R.; Kim Y.J.; Kisa A.; Kisa S.; Skarbek K.K.; Kopec J.A.; Koteeswaran R.; Koul P.A.; Laxminarayana K.S.L.; Koyanagi A.; Bicer K.B.; Kugbey N.; Kumar G.A.; Kumar N.; Kumar N.; Kurmi O.P.; Kutluk T.; Vecchia L.C.; Lami F.H.; Landires I.; Lauriola P.; Lee S.; Lee S.W.H.; Lee W.C.; Lee Y.H.; Leigh J.; Leong E.; Li J.; Li M.C.; Liu X.; Loureiro J.A.; Lunevicius R.; Magdy Abd El Razek M.; Majeed A.; Makki A.; Male S.; Malik A.A.; Mansournia M.A.; Martini S.; Masoumi S.Z.; Mathur P.; McKee M.; Mehrotra R.; Mendoza W.; Menezes R.G.; Mengesha E.W.; Mesregah M.K.; Mestrovic T.; Jonasson M.J.; Miazgowski B.; Miazgowski T.; Michalek I.M.; Miller T.R.; Mirzaei H.; Mirzaei H.R.; Misra S.; Mithra P.; Moghadaszadeh M.; Mohammad K.A.; Mohammad Y.; Mohammadi M.; Mohammadi S.M.; Hafshejani M.A.; Mohammed S.; Moka N.; Mokdad A.H.; Molokhia M.; Monasta L.; Moni M.A.; Moosavi M.A.; Moradi Y.; Moraga P.; Morgado-da-Costa J.; Morrison S.D.; Mosapour A.; Mubarik S.; Mwanri L.; Nagarajan A.J.; Nagaraju S.P.; Nagata C.; Naimzada M.D.; Nangia V.; Naqvi A.A.; Swamy N.S.; Ndejjo R.; Nduaguba S.O.; Negoi I.; Negru S.M.; Kandel N.S.; Nguyen C.T.; Nguyen H.L.T.; Niazi R.K.; Nnaji C.A.; Noor N.M.; Samudio N.V.; Nzoputam C.I.; Oancea B.; Ochir C.; Odukoya O.O.; Ogbo F.A.; Olagunju A.T.; Olakunde B.O.; Omar E.; Bali O.A.; Omonisi A.E.E.; Ong S.; Onwujekwe O.E.; Orru H.; Altamirano O.D.V.; Otstavnov N.; Otstavnov S.S.; Owolabi M.O.; \/surname> P.M.; Padubidri J.R.; Pakshir K.; Pana A.; Panagiotakos D.; Jonas P.S.; Pardhan S.; Park E.C.; Park E.K.; Kan P.F.; Patel H.K.; Patel J.R.; Pati S.; Pattanshetty S.M.; Paudel U.; Pereira D.M.; Pereira R.B.; Perianayagam A.; Pillay J.D.; Pirouzpanah S.; Pishgar F.; Podder I.; Postma M.J.; Pourjafar H.; Prashant A.; Preotescu L.; Rabiee M.; Rabiee N.; Radfar A.; Radhakrishnan R.A.; Radhakrishnan V.; Rafiee A.; Rahim F.; Rahimzadeh S.; Rahman M.; Rahman M.A.; Rahmani A.M.; Rajai N.; Rajesh A.; Rakovac I.; Ram P.; Ramezanzadeh K.; Ranabhat K.; Ranasinghe P.; Rao C.R.; Rao S.J.; Rawassizadeh R.; Razeghinia M.S.; Renzaho A.M.N.; Rezaei N.; Rezaei N.; Rezapour A.; Roberts T.J.; Rodriguez J.A.B.; Rohloff P.; Romoli M.; Ronfani L.; Roshandel G.; Rwegerera G.M.; S M.; Sabour S.; Saddik B.; Saeed U.; Sahebkar A.; Sahoo H.; Salehi S.; Salem M.R.; Salimzadeh H.; Samaei M.; Samy A.M.; Sanabria J.; Sankararaman S.; Milicevic S.M.M.; Sardiwalla Y.; Sarveazad A.; Sathian B.; Sawhney M.; Saylan M.; Schneider I.J.C.; Sekerija M.; Seylani A.; Shafaat O.; Shaghaghi Z.; Shaikh M.A.; Shamsoddin E.; Shannawaz M.; Sharma R.; Sheikh A.; Sheikhbahaei S.; Shetty A.; Shetty J.K.; Shetty P.H.; Shibuya K.; Shirkoohi R.; Shivakumar K.M.; Shivarov V.; Siabani S.; Malleshappa S.S.K.; Silva D.A.S.; Singh J.A.; Sintayehu Y.; Skryabin V.Y.; Skryabina A.A.; Soeberg M.J.; Mahmudi S.A.; Sotoudeh H.; Steiropoulos P.; Straif K.; Subedi R.; Sufiyan M.B.; Sultan I.; Sultana S.; Sur D.; Szerencs\u00e9s V.; Sz\u00f3cska M.; Seisdedos T.R.; Tabuchi T.; Tadbiri H.; Taherkhani A.; Takahashi K.; Talaat I.M.; Tan K.K.; Tat V.Y.; Tedla B.A.A.; Tefera Y.G.; Banihashemi T.A.; Temsah M.H.; Tesfay F.H.; Tessema G.A.; Thapar R.; Thavamani A.; Chandrasekar T.V.; Thomas N.; Tohidinik H.R.; Touvier M.; Palone T.M.R.; Traini E.; Tran B.X.; Tran K.B.; Tran M.T.N.; Tripathy J.P.; Tusa B.S.; Ullah I.; Ullah S.; Umapathi K.K.; Unnikrishnan B.; Upadhyay E.; Vacante M.; Vaezi M.; Tahbaz V.S.; Velazquez D.Z.; Veroux M.; Violante F.S.; Vlassov V.; Vo B.; Volovici V.; Vu G.T.; Waheed Y.; Wamai R.G.; Ward P.; Wen Y.F.; Westerman R.; Winkler A.S.; Yadav L.; Jabbari Y.S.H.; Yang L.; Yaya S.; Yazie T.S.Y.; Yeshaw Y.; Yonemoto N.; Younis M.Z.; Yousefi Z.; Yu C.; Yuce D.; Yunusa I.; Zadnik V.; Zare F.; Zastrozhin M.S.; Zastrozhina A.; Zhang J.; Zhong C.; Zhou L.; Zhu C.; Ziapour A.; Zimmermann I.R.; Fitzmaurice C.; Murray C.J.L.; Force L.M.; Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the global burden of disease study 2019. JAMA Oncol  2022,8(3),420-444","journal-title":"JAMA Oncol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/npp.2008.173","volume":"34","author":"Markou A.","year":"2009","unstructured":"Markou A.; Chiamulera C.; Geyer M.A.; Tricklebank M.; Steckler T.; Removing obstacles in neuroscience drug discovery: The future path for animal models. Neuropsychopharmacology  2009,34(1),74-89","journal-title":"Neuropsychopharmacology"},{"key":"ref=54","first-page":"467","volume":"81","author":"Umbricht D","year":"2020","unstructured":"Umbricht D; Niggli M; Ducray S.P; Deptula D; Moore R; Gr\u00fcnbauer W; Boak L; Fontoura P.; Randomized, double-blind, placebo-controlled trial of the mGlu2\/3 negative allosteric modulator decoglurant in partially refractory major depressive disorder. J Clin Psych  2020,81(4),467","journal-title":"J Clin Psych"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1021\/acsmedchemlett.7b00249","volume":"8","author":"Engers J.L.","year":"2017","unstructured":"Engers J.L.; Bollinger K.A.; Weiner R.L.; Rodriguez A.L.; Long M.F.; Breiner M.M.; Chang S.; Bollinger S.R.; Bubser M.; Jones C.K.; Morrison R.D.; Bridges T.M.; Blobaum A.L.; Niswender C.M.; Conn P.J.; Emmitte K.A.; Lindsley C.W.; Design and synthesis of N-aryl phenoxyethoxy pyridinones as highly selective and CNS penetrant mGlu3 NAMs. ACS Med Chem Lett  2017,8(9),925-930","journal-title":"ACS Med Chem Lett"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuropharm.2012.08.001","volume":"64","author":"Goeldner C.","year":"2013","unstructured":"Goeldner C.; Ballard T.M.; Knoflach F.; Wichmann J.; Gatti S.; Umbricht D.; Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology  2013,64,337-346","journal-title":"Neuropharmacology"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1111\/j.1471-4159.2010.07066.x","volume":"115","author":"Hascup E.R.","year":"2010","unstructured":"Hascup E.R.; Hascup K.N.; Stephens M.; Pomerleau F.; Huettl P.; Gratton A.; Gerhardt G.A.; Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex. J Neurochem  2010,115(6),1608-1620","journal-title":"J Neurochem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.4088\/JCP.12m07706","volume":"73","author":"Khajavi D.","year":"2012","unstructured":"Khajavi D.; Farokhnia M.; Modabbernia A.; Ashrafi M.; Abbasi S.H.; Tabrizi M.; Akhondzadeh S.; Oral scopolamine augmentation in moderate to severe major depressive disorder: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry  2012,73(11),1428-1433","journal-title":"J Clin Psychiatry"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"130369","DOI":"10.1016\/j.molstruc.2021.130369","volume":"1237","author":"Singh K.","year":"2021","unstructured":"Singh K.; Pal R.; Khan S.A.; Kumar B.; Akhtar M.J.; Insights into the structure activity relationship of nitrogen-containing heterocyclics for the development of antidepressant compounds: An updated review. J Mol Struct  2021,1237,130369","journal-title":"J Mol Struct"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.3390\/molecules26113320","volume":"26","author":"Sirakanyan S.N.","year":"2021","unstructured":"Sirakanyan S.N.; Spinelli D.; Geronikaki A.; Kartsev V.; Hakobyan E.K.; Petrou A.; Paronikyan R.G.; Nazaryan I.M.; Akopyan H.H.; Hovakimyan A.A.; Synthesis and Neurotropic Activity of New Heterocyclic Systems: Pyridofuro[3,2-d]pyrrolo[1,2-a]pyrimidines, Pyridofuro[3,2-d]pyrido[1,2-a]pyrimidines and Pyridofuro[3\u2032,2\u2032: 4,5]pyrimido[1,2-a]azepines. Molecules  2021,26(11),3320","journal-title":"Molecules"},{"key":"ref=61","first-page":"CD003197","volume":"2003","author":"Furukawa T.","year":"2003","unstructured":"Furukawa T.; McGuire H.; Barbui C.; Low dosage tricyclic antidepressants for depression. Cochrane Database Syst Rev  2003,2003(3),CD003197","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"588","DOI":"10.5498\/wjp.v12.i4.588","volume":"12","author":"Mu\u00f1oz L.F.","year":"2022","unstructured":"Mu\u00f1oz L.F.; D\u2019Oc\u00f3n P.; Romero A.; Guerra J.A.; \u00c1lamo C.; Role of serendipity in the discovery of classical antidepressant drugs: Applying operational criteria and patterns of discovery. World J Psychiatry  2022,12(4),588-602","journal-title":"World J Psychiatry"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12964-023-01128-x","volume":"21","author":"Mu W.","year":"2023","unstructured":"Mu W.; Xu G.; Wang Z.; Li Q.; Sun S.; Qin Q.; Li Z.; Shi W.; Dai W.; Zhan X.; Wang J.; Bai Z.; Xiao X.; Tricyclic antidepressants induce liver inflammation by targeting NLRP3 inflammasome activation. Cell Commun Signal  2023,21(1),123","journal-title":"Cell Commun Signal"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/med.21852","volume":"42","author":"Laxmikeshav K.","year":"2022","unstructured":"Laxmikeshav K.; Kumari P.; Shankaraiah N.; Expedition of sulfur-containing heterocyclic derivatives as cytotoxic agents in medicinal chemistry: A decade update. Med Res Rev  2022,42(1),513-575","journal-title":"Med Res Rev"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/B978-0-12-817592-7.00020-4","author":"Banik BK","year":"2024","unstructured":"Banik BK; Sahoo BM; Kumar BR; Panda J; Kumar A; Green chemistry and synthetic approaches in the development of antidepressant and antipsychotic agents. Green approaches in medicinal chemistry for sustainable drug design  2024,513-530","journal-title":"Green approaches in medicinal chemistry for sustainable drug design"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/ardp.200900244","volume":"343","author":"Elmegeed G.A.","year":"2010","unstructured":"Elmegeed G.A.; Baiuomy A.R.; Abdelhalim M.M.; Hana H.Y.; Synthesis and antidepressant evaluation of five novel heterocyclic tryptophan-hybrid derivatives. Arch Pharm  2010,343(5),261-267","journal-title":"Arch Pharm"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4103\/0975-7406.80765","volume":"3","author":"Bawa S.","year":"2011","unstructured":"Bawa S.; Siddiqui N.; Andalip ; Ali R.; Afzal O.; Akhtar M.J.; Azad B.; Kumar R.; Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review. J Pharm Bioallied Sci  2011,3(2),194-212","journal-title":"J Pharm Bioallied Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"14041","DOI":"10.3390\/ijms232214041","volume":"23","author":"Carboni L.","year":"2022","unstructured":"Carboni L.; Rullo L.; Caputi F.F.; Stamatakos S.; Candeletti S.; Romualdi P.; Chronic trazodone and citalopram treatments increase trophic factor and circadian rhythm gene expression in rat brain regions relevant for antidepressant efficacy. Int J Mol Sci  2022,23(22),14041","journal-title":"Int J Mol Sci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1517\/14656566.2016.1133587","volume":"17","author":"Goracci A.","year":"2016","unstructured":"Goracci A.; Forgione R.N.; Giorgi D.R.; Coluccia A.; Cuomo A.; Fagiolini A.; Practical guidance for prescribing trazodone extended-release in major depression. Expert Opin Pharmacother  2016,17(3),433-441","journal-title":"Expert Opin Pharmacother"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"Cipriani A.","year":"2018","unstructured":"Cipriani A.; Furukawa T.A.; Salanti G.; Chaimani A.; Atkinson L.Z.; Ogawa Y.; Leucht S.; Ruhe H.G.; Turner E.H.; Higgins J.P.T.; Egger M.; Takeshima N.; Hayasaka Y.; Imai H.; Shinohara K.; Tajika A.; Ioannidis J.P.A.; Geddes J.R.; Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet  2018,391(10128),1357-1366","journal-title":"Lancet"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/PPA.S29716","volume":"6","author":"harbi A.K.S.","year":"2012","unstructured":"harbi A.K.S.; Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient Prefer Adherence  2012,6,369-388","journal-title":"Patient Prefer Adherence"},{"key":"ref=72","first-page":"272","volume":"25","author":"Peselow E.D.","year":"1989","unstructured":"Peselow E.D.; Filippi A.M.; Goodnick P.; Barouche F.; Fieve R.R.; The short- and long-term efficacy of paroxetine HCl: B. Data from a double-blind crossover study and from a year-long term trial vs. imipramine and placebo. Psychopharmacol Bull  1989,25(2),272-276","journal-title":"Psychopharmacol Bull"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11920-013-0403-2","volume":"15","author":"Thase M.E.","year":"2013","unstructured":"Thase M.E.; Antidepressant combinations: Cutting edge psychopharmacology or passing fad? Curr Psychiatry Rep  2013,15(10),403","journal-title":"Curr Psychiatry Rep"},{"key":"ref=74","first-page":"301","volume":"1","author":"Moret C.","year":"2005","unstructured":"Moret C.; Combination\/augmentation strategies for improving the treatment of depression. Neuropsychiatr Dis Treat  2005,1(4),301-309","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archpsyc.1991.01810280019002","volume":"48","author":"Nelson J.C.","year":"1991","unstructured":"Nelson J.C.; Mazure C.M.; Bowers M.B.; Jatlow P.I.; A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry  1991,48(4),303-307","journal-title":"Arch Gen Psychiatry"},{"key":"ref=76","first-page":"291","volume":"7","author":"Holland J.C.","year":"1998","unstructured":"Holland J.C.; Romano S.J.; Heiligenstein J.H.; Tepner R.G.; Wilson M.G.; A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-Oncology: Journal of the Psychological. Soc Behav Dimen Cancer  1998,7(4),291-300","journal-title":"Soc Behav Dimen Cancer"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","volume":"124","author":"Egan B.M.","year":"2011","unstructured":"Egan B.M.; Zhao Y.; Axon R.N.; Brzezinski W.A.; Ferdinand K.C.; Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation  2011,124(9),1046-1058","journal-title":"Circulation"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/depr.3050020307","volume":"2","author":"Thase M.E.","year":"1994","unstructured":"Thase M.E.; Rush A.J.; Kasper S.; Nemeroff C.B.; Tricyclics and newer antidepressant medications: Treatment options for treatment-resistant depressions. Depression  1994,2(3),152-168","journal-title":"Depression"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","volume":"151","author":"Gillman P.K.","year":"2007","unstructured":"Gillman P.K.; Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol  2007,151(6),737-748","journal-title":"Br J Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/iwj.12884","volume":"15","author":"Pinheiro R.R.","year":"2018","unstructured":"Pinheiro R.R.; Duarte B.; Cabete J.; Trichloroacetic acid (80%) as a chemical debridement method for chronic venous leg ulcers-A pilot study. Int Wound J  2018,15(3),438-440","journal-title":"Int Wound J"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nrn2297","volume":"9","author":"Dantzer R.","year":"2008","unstructured":"Dantzer R.; O\u2019Connor J.C.; Freund G.G.; Johnson R.W.; Kelley K.W.; From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci  2008,9(1),46-56","journal-title":"Nat Rev Neurosci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3389\/fpsyg.2017.01561","volume":"8","author":"Hestad K.A.","year":"2017","unstructured":"Hestad K.A.; Engedal K.; Whist J.E.; Farup P.G.; The relationships among tryptophan, kynurenine, indoleamine 2, 3-dioxygenase, depression, and neuropsychological performance. Front Psychol  2017,8,1561","journal-title":"Front Psychol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/7854_2016_6","volume":"31","author":"Dantzer R.","year":"2017","unstructured":"Dantzer R.; Role of the kynurenine metabolism pathway in inflammation-induced depression: Preclinical approaches. Curr Top Behav Neurosci  2017,31,117-138","journal-title":"Curr Top Behav Neurosci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/ijms25020853","volume":"25","author":"Pathak S.","year":"2024","unstructured":"Pathak S.; Nadar R.; Kim S.; Liu K.; Govindarajulu M.; Cook P.; Alexander W.C.S.; Dhanasekaran M.; Moore T.; The influence of kynurenine metabolites on neurodegenerative pathologies. Int J Mol Sci  2024,25(2),853","journal-title":"Int J Mol Sci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"297","DOI":"10.5498\/wjp.v11.i7.297","volume":"11","author":"Onaolapo A.Y.","year":"2021","unstructured":"Onaolapo A.Y.; Onaolapo O.J.; Glutamate and depression: Reflecting a deepening knowledge of the gut and brain effects of a ubiquitous molecule. World J Psychiatry  2021,11(7),297-315","journal-title":"World J Psychiatry"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.neuropharm.2016.01.034","volume":"112","author":"Bryleva E.Y.","year":"2017","unstructured":"Bryleva E.Y.; Brundin L.; Kynurenine pathway metabolites and suicidality. Neuropharmacology  2017,112(Pt B),324-330","journal-title":"Neuropharmacology"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/gps.930100209","volume":"10","author":"Flint A.J.","year":"1995","unstructured":"Flint A.J.; Augmentation strategies in geriatric depression. Int J Geriatr Psychiatry  1995,10(2),137-146","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5498\/wjp.v11.i7.277","volume":"11","author":"\u013dupt\u00e1k M.","year":"2021","unstructured":"\u013dupt\u00e1k M.; Michali\u010dkov\u00e1 D.; Fi\u0161ar Z.; Kitzlerov\u00e1 E.; Hroudov\u00e1 J.; Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. World J Psychiatry  2021,11(7),277-296","journal-title":"World J Psychiatry"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1055\/s-0043-112345","volume":"50","author":"Wincewicz D.","year":"2017","unstructured":"Wincewicz D.; Braszko J.; Validation of brain angiotensin system blockade as a novel drug target in pharmacological treatment of neuropsychiatric disorders. Pharmacopsychiatry  2017,50(6),233-247","journal-title":"Pharmacopsychiatry"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1517\/13543784.12.1.65","volume":"12","author":"Farvolden P.","year":"2003","unstructured":"Farvolden P.; Kennedy S.H.; Lam R.W.; Recent developments in the psychobiology and pharmacotherapy of depression: Optimising existing treatments and novel approaches for the future. Expert Opin Investig Drugs  2003,12(1),65-86","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1005702","DOI":"10.3389\/fphar.2022.1005702","volume":"13","author":"Jiao S.","year":"2022","unstructured":"Jiao S.; Cao T.; Cai H.; Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives. Front Pharmacol  2022,13,1005702","journal-title":"Front Pharmacol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/17460441.2014.857309","volume":"9","author":"Stewart A.M.","year":"2014","unstructured":"Stewart A.M.; Kalueff A.V.; Anxiolytic drug discovery: What are the novel approaches and how can we improve them? Expert Opin Drug Discov  2014,9(1),15-26","journal-title":"Expert Opin Drug Discov"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/ph15010046","volume":"15","author":"Tang J.","year":"2021","unstructured":"Tang J.; Chen L.R.; Chen K.H.; The utilization of dehydroepiandrosterone as a sexual hormone precursor in premenopausal and postmenopausal women: An overview. Pharmaceuticals  2021,15(1),46","journal-title":"Pharmaceuticals"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0079-6123(10)82004-7","volume":"182","author":"Labrie F.","year":"2010","unstructured":"Labrie F.; DHEA, important source of sex steroids in men and even more in women. Prog Brain Res  2010,182,97-148","journal-title":"Prog Brain Res"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3390\/cells11061038","volume":"11","author":"Kilanczyk E.","year":"2022","unstructured":"Kilanczyk E.; Ruminkiewicz D.; Banales J.M.; Milkiewicz P.; Milkiewicz M.; DHEA protects human cholangiocytes and hepatocytes against apoptosis and oxidative stress. Cells  2022,11(6),1038","journal-title":"Cells"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"100041","DOI":"10.1016\/j.cpnec.2021.100041","volume":"6","author":"Misiak B.","year":"2021","unstructured":"Misiak B.; Piotrowski P.; Ch\u0119\u0107 M.; Samochowiec J.; Cortisol and dehydroepiandrosterone sulfate in patients with schizophrenia spectrum disorders with respect to cognitive performance. Compr Psychoneuroendocrinol  2021,6,100041","journal-title":"Compr Psychoneuroendocrinol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S1566-2772(02)00044-0","volume":"2","author":"Gould T.D.","year":"2002","unstructured":"Gould T.D.; Chen G.; Manji H.K.; Mood stabilizer psychopharmacology. Clin Neurosci Res  2002,2(3-4),193-212","journal-title":"Clin Neurosci Res"},{"key":"ref=98","first-page":"74","volume":"1","author":"Leo R.J.","year":"1999","unstructured":"Leo R.J.; Narendran R.; Anticonvulsant use in the treatment of bipolar disorder: A primer for primary care physicians. Prim Care Companion J Clin Psychiatry  1999,1(3),74-84","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/medicina57050433","volume":"57","author":"Grunze A.","year":"2021","unstructured":"Grunze A.; Amann B.L.; Grunze H.; Efficacy of carbamazepine and its derivatives in the treatment of bipolar disorder. Medicina  2021,57(5),433","journal-title":"Medicina"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fneng.2010.00007","volume":"3","author":"Ward M.P.","year":"2010","unstructured":"Ward M.P.; Irazoqui P.P.; Evolving refractory major depressive disorder diagnostic and treatment paradigms: Toward closed-loop therapeutics. Front Neuroeng  2010,3,7","journal-title":"Front Neuroeng"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"165","DOI":"10.31887\/DCNS.2008.10.2\/evieta","volume":"10","author":"Vieta E.","year":"2008","unstructured":"Vieta E.; Moreno S.J.; Acute and long-term treatment of mania. Dialogues Clin Neurosci  2008,10(2),165-179","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1192\/bjp.187.3.229","volume":"187","author":"Khanna S.","year":"2005","unstructured":"Khanna S.; Vieta E.; Lyons B.; Grossman F.; Eerdekens M.; Kramer M.; Risperidone in the treatment of acute mania. Br J Psychiatry  2005,187(3),229-234","journal-title":"Br J Psychiatry"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fpsyt.2019.00210","volume":"10","author":"Polese D.","year":"2019","unstructured":"Polese D.; Fornaro M.; Palermo M.; Luca D.V.; Bartolomeis d.A.; Treatment-resistant to antipsychotics: A resistance to everything? Psychotherapy in treatment-resistant schizophrenia and nonaffective psychosis: A 25-year systematic review and exploratory meta-analysis. Front Psychiatry  2019,10,210","journal-title":"Front Psychiatry"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jad.2016.12.013","volume":"210","author":"Kolovos S.","year":"2017","unstructured":"Kolovos S.; Tulder v.M.W.; Cuijpers P.; Prigent A.; Chevreul K.; Riper H.; Bosmans J.E.; The effect of treatment as usual on major depressive disorder: A meta-analysis. J Affect Disord  2017,210,72-81","journal-title":"J Affect Disord"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","volume":"14","author":"Bonson K.","year":"1996","unstructured":"Bonson K.; Buckholtz J.W.; Murphy D.L.; Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology  1996,14(6),425-436","journal-title":"Neuropsychopharmacology"},{"key":"ref=106","author":"Petermann F.","year":"2015","unstructured":"Petermann F.; Hospital anxiety and depression scale, deutsche version (HADS-D). Z Psychiatr Psychol Psychother  2015","journal-title":"Z Psychiatr Psychol Psychother"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"Gasser P.","year":"2014","unstructured":"Gasser P.; Holstein D.; Michel Y.; Doblin R.; Klosinski Y.B.; Passie T.; Brenneisen R.; Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis  2014,202(7),513-520","journal-title":"J Nerv Ment Dis"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.pnpbp.2010.02.008","volume":"34","author":"P\u00e1len\u00ed\u010dek T.","year":"2010","unstructured":"P\u00e1len\u00ed\u010dek T.; Hli\u0148\u00e1k Z.; Buben\u00edkov\u00e1-Vale\u0161ov\u00e1 V.; Nov\u00e1k T.; Hor\u00e1\u010dek J.; Sex differences in the effects of N,N-diethyllysergamide (LSD) on behavioural activity and prepulse inhibition. Prog Neuropsychopharmacol Biol Psychiatry  2010,34(4),588-596","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1177\/0269881118771782","volume":"32","author":"Thiessen M.S.","year":"2018","unstructured":"Thiessen M.S.; Walsh Z.; Bird B.M.; Lafrance A.; Psychedelic use and intimate partner violence: The role of emotion regulation. J Psychopharmacol  2018,32(7),749-755","journal-title":"J Psychopharmacol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"Harris C.R.L.","year":"2018","unstructured":"Harris C.R.L.; Bolstridge M.; Day C.M.J.; Rucker J.; Watts R.; Erritzoe D.E.; Kaelen M.; Giribaldi B.; Bloomfield M.; Pilling S.; Rickard J.A.; Forbes B.; Feilding A.; Taylor D.; Curran H.V.; Nutt D.J.; Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology  2018,235(2),399-408","journal-title":"Psychopharmacology"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"Roseman L.","year":"2018","unstructured":"Roseman L.; Nutt D.J.; Harris C.R.L.; Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol  2018,8,974","journal-title":"Front Pharmacol"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1037\/adb0000935","volume":"38","author":"Liebes A.G.","year":"2019","unstructured":"Liebes A.G.; The role of self-compassion in psilocybin-assisted motivational enhancement therapy to treat alcohol dependence: A randomized controlled trial. Psychol Addict Behav  2019,38(1),101-113","journal-title":"Psychol Addict Behav"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1172\/JCI130808","volume":"130","author":"Gerhard D.M.","year":"2020","unstructured":"Gerhard D.M.; Pothula S.; Liu R.J.; Wu M.; Li X.Y.; Girgenti M.J.; Taylor S.R.; Duman C.H.; Delpire E.; Picciotto M.; Wohleb E.S.; Duman R.S.; GABA interneurons are the cellular trigger for ketamine\u2019s rapid antidepressant actions. J Clin Invest  2020,130(3),1336-1349","journal-title":"J Clin Invest"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.neuron.2020.05.015","volume":"106","author":"Kavalali E.T.","year":"2020","unstructured":"Kavalali E.T.; Monteggia L.M.; Targeting homeostatic synaptic plasticity for treatment of mood disorders. Neuron  2020,106(5),715-726","journal-title":"Neuron"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1177\/0271678X19886316","volume":"40","author":"Holmes S.E.","year":"2020","unstructured":"Holmes S.E.; Gallezot J.D.; Davis M.T.; DellaGioia N.; Matuskey D.; Nabulsi N.; Krystal J.H.; Javitch J.A.; DeLorenzo C.; Carson R.E.; Esterlis I.; Measuring the effects of ketamine on mGluR5 using [  F]FPEB and PET. J Cereb Blood Flow Metab  2020,40(11),2254-2264","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1172\/JCI126859","volume":"129","author":"Kato T.","year":"2019","unstructured":"Kato T.; Pothula S.; Liu R.J.; Duman C.H.; Terwilliger R.; Vlasuk G.P.; Saiah E.; Hahm S.; Duman R.S.; Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. J Clin Invest  2019,129(6),2542-2554","journal-title":"J Clin Invest"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pscychresns.2016.06.006","volume":"254","author":"Nugent A.C.","year":"2016","unstructured":"Nugent A.C.; Robinson S.E.; Coppola R.; Zarate C.A.; Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder. Psychiatry Res Neuroimaging  2016,254,56-66","journal-title":"Psychiatry Res Neuroimaging"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/npp.2016.186","volume":"42","author":"Abdallah C.G.","year":"2017","unstructured":"Abdallah C.G.; Averill L.A.; Collins K.A.; Geha P.; Schwartz J.; Averill C.; DeWilde K.E.; Wong E.; Anticevic A.; Tang C.Y.; Iosifescu D.V.; Charney D.S.; Murrough J.W.; Ketamine treatment and global brain connectivity in major depression. Neuropsychopharmacology  2017,42(6),1210-1219","journal-title":"Neuropsychopharmacology"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"e15070","DOI":"10.7759\/cureus.15070","volume":"13","author":"Tedesco S.","year":"2021","unstructured":"Tedesco S.; Gajaram G.; Chida S.; Ahmad A.; Pentak M.; Kelada M.; Lewis L.; Krishnan D.; Tran C.; Soetan O.T.; Mukona L.T.; Jolayemi A.; The efficacy of MDMA (3, 4-Methylenedioxymethamphetamine) for post-traumatic stress disorder in humans: A systematic review and meta-analysis. Cureus  2021,13(5),e15070","journal-title":"Cureus"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/diseases11040159","volume":"11","author":"Riaz K.","year":"2023","unstructured":"Riaz K.; Suneel S.; Hamza Bin Abdul Malik M.; Kashif T.; Ullah I.; Waris A.; Nicola D.M.; Mazza M.; Sani G.; Martinotti G.; Berardis D.D.; MDMA-based psychotherapy in treatment-resistant post-traumatic stress disorder (PTSD): A brief narrative overview of current evidence. Diseases  2023,11(4),159","journal-title":"Diseases"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1038\/s41598-017-05407-9","volume":"7","author":"Garc\u00eda M.J.A.","year":"2017","unstructured":"Garc\u00eda M.J.A.; de la Fuente Revenga M.; Gil A.S.; Franco R.M.I.; Feilding A.; Castillo P.A.; Riba J.; The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Sci Rep  2017,7(1),5309","journal-title":"Sci Rep"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","volume":"37","author":"Os\u00f3rio F.L.","year":"2015","unstructured":"Os\u00f3rio F.L.; Sanches R.F.; Macedo L.R.; Santos d.R.G.; Maia-de-Oliveira J.P.; Ana W.L.; Araujo d.D.B.; Riba J.; Crippa J.A.; Hallak J.E.; Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. Rev Bras Psiquiatr  2015,37(1),13-20","journal-title":"Rev Bras Psiquiatr"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1271152","DOI":"10.3389\/fpsyt.2023.1271152","volume":"14","author":"Ragnhildstveit A.","year":"2023","unstructured":"Ragnhildstveit A.; Khan R.; Seli P.; Bass L.C.; August R.J.; Kaiyo M.; Barr N.; Jackson L.K.; Gaffrey M.S.; Barsuglia J.P.; Averill L.A.; 5-MeO-DMT for post-traumatic stress disorder: A real-world longitudinal case study. Front Psychiatry  2023,14,1271152","journal-title":"Front Psychiatry"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jnc.15587","volume":"162","author":"Reckweg J.T.","year":"2022","unstructured":"Reckweg J.T.; Uthaug M.V.; Szabo A.; Davis A.K.; Lancelotta R.; Mason N.L.; Ramaekers J.G.; The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). J Neurochem  2022,162(1),128-146","journal-title":"J Neurochem"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/02698811211050543","volume":"36","author":"Ermakova A.O.","year":"2022","unstructured":"Ermakova A.O.; Dunbar F.; Rucker J.; Johnson M.W.; A narrative synthesis of research with 5-MeO-DMT. J Psychopharmacol  2022,36(3),273-294","journal-title":"J Psychopharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s41470-019-00063-y","volume":"61","author":"Germann C.B.","year":"2019","unstructured":"Germann C.B.; 5-methoxy-N, N-dimethyltryptamine: An ego-dissolving endogenous neurochemical catalyst of creativity. Act Nerv Super  2019,61(4),170-216","journal-title":"Act Nerv Super"},{"key":"ref=127","author":"Rush B","year":"2022","unstructured":"Rush B; Marcus O; Shore R; Cunningham L; Thompson N; Rideout K.;  Psychedelic medicine: A rapid review of therapeutic applications and implications for future research  2022","journal-title":"Psychedelic medicine: A rapid review of therapeutic applications and implications for future research"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/bs13040297","volume":"13","author":"Dawood Hristova J.J.","year":"2023","unstructured":"Dawood Hristova J.J.; P\u00e9rez-Jover V.; Psychotherapy with psilocybin for depression: systematic review. Behav Sci (Basel)  2023,13(4),297","journal-title":"Behav Sci (Basel)"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673342524250109181220","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/242256\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673342524250109181220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:04:24Z","timestamp":1772085864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/242256\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":128,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673342524250109181220","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}